Shire presents positive trial data for type 1 Gaucher disease drug

Shire has published clinical trial data which supports the efficacy of Vpriv, its treatment for sufferers of type 1 Gaucher disease.

Findings from the phase III study showed that patients were able to safely switch from an imiglucerase therapy to using Vpriv without any adverse safety effects, while maintaining effective treatment results.

Moreover, those trialled with Vpriv exhibited stable therapeutic levels of haemoglobin concentration, platelet counts and liver and spleen volumes throughout the year-long study.

These findings mean that the drug was able to meet both its primary and secondary endpoints in the trial.

Dr Gregory Grabowski, of Cincinnati Children’s Hospital Medical Center and principal investigator for the study, stated that this information “should help inform treatment decisions” when dealing with the disease.

Earlier this month, Shire announced the appointment of former Roche chief executive Bill Burns to a position on its corporate board as a non-executive director.